Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04912596
Other study ID # TW20-4643
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 15, 2022
Est. completion date April 2024

Study information

Verified date February 2024
Source Intech Biopharm Ltd.
Contact Jasmine Kuo
Phone +886-2-7721-8877
Email jasmine.i199@intechbiopharm.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to evaluate the pharmacodynamic (PD) bioequivalence (BE) of albuterol inhalers, test formulation: Albuterol Sulfate HFA inhalation aerosol 108 mcg (equal to albuterol base 90 mcg) per actuation and reference formulation: ProAir HFA (albuterol sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg (equal to albuterol base 90 mcg) per actuation manufactured by two different manufacturers using methacholine bronchoprovocation challenge test in patients with stable mild asthma.


Description:

This study will be conducted using the single-dose, randomized, double-blind, double-dummy, four-sequence, four-treatment, and multiple-center study design to evaluate the PD bioequivalence between the test albuterol sulfate (T) inhalation aerosol 108 mcg per actuation (eq. to albuterol base 90 mcg/puff) and the reference albuterol sulfate (R) (ProAir HFA or FDA authorized generic: Albuterol Sulfate HFA [Teva Pharmaceutical USA, Inc.]) inhalation aerosol 108 mcg per actuation (equal to albuterol base 90 mcg/puff). The two products will be studied using a crossover design in patients with stable mild asthma by administering a minimum of 3 doses of reference product (0, 90, 180 mcg albuterol) and 2 doses of test product (0, 90 mcg albuterol). The bronchodilation potency of albuterol sulfate are measured by the inhibition effects of methacholine challenge on the bronchodilation, as indicated by increase in the provocative concentration of methacholine required to produce a 20% decrease in FEV1 (PC20).


Recruitment information / eligibility

Status Recruiting
Enrollment 148
Est. completion date April 2024
Est. primary completion date March 2024
Accepts healthy volunteers No
Gender All
Age group 20 Years to 65 Years
Eligibility Inclusion Criteria: 1. Male, non-pregnant and non-lactating female subjects (20-65 years of age, inclusive). 2. A clinical diagnosis of mild asthma with historical documentation of the asthma diagnosis according to either: (1) the National Asthma Education and Prevention Program (NAEPP) guidelines (2007) or (2) the Global Initiative for Asthma (GINA) Global Strategy for Asthma Management and Prevention (2020). 3. Stable mild asthma receiving the following required inhaled medications for at least 1 month prior to screening: Low doses of ICS alone, or in combination with SABA, used regularly with a stable regimen. 4. Forced Expiratory Volume in 1 second (FEV1) = 80% of the local predicted normal value after withholding SABA = 8 hours. 5. Airway responsiveness to methacholine demonstrated by a pre-albuterol-dose (baseline) PC20 = 8 mg/mL. 6. Nonsmoker for at least 6 months prior to the study and a maximum smoking history of 5 pack-years (the equivalent of one pack per day for 5 years). 7. Provision of written informed consent. 8. Other than asthma, in general good health. 9. Body mass index (BMI) between 17 and 35 kg/m2 (inclusive). 10. Able to correctly use MDI inhalers. 11. Able to perform valid and reproducible pulmonary function tests including no evidence of spirometry effort-induced bronchoconstriction. 12. If the subject or subject's partner is of child-bearing potential, a medically acceptable form of contraception will be used for the duration of the study. Medically acceptable contraceptives include: (1) surgical sterilization, (2) Health Authority approved female hormonal contraceptives, (3) an intrauterine device (IUD), (4) condoms with spermicide, or (5) diaphragm with spermicide. Exclusion Criteria: 1. Evidence of conditions altering airway reactivity to methacholine, including upper or lower respiratory tract infections (e.g., pneumonia, viral bronchitis, allergic rhinitis, sinobronchitis, etc.) within 6 weeks before Screening. 2. Evidence of a baseline FEV1 < 60% of the local predicted normal value or FEV1 < 1.5 L. 3. History of seasonal asthma exacerbations, in which case the subject should be studied outside of the relevant allergen season. 4. History of cystic fibrosis, bronchiectasis, COPD, or other respiratory diseases including COPD, chronic bronchitis, emphysema, tuberculosis, pulmonary carcinoma, pulmonary fibrosis, pulmonary hypertension that, in the opinion of the Investigator, would compromise subject safety or interfere with the evaluations. 5. History of cardiovascular, hematological, renal, neurologic, hepatic, psychiatric, endocrine dysfunction, including ECG with evidence of ischemic heart diseases and significant arrhythmias. 6. Treatment in an emergency room or hospitalization for acute asthmatic symptoms within 3 months prior to screening. 7. Known intolerance or hypersensitivity to any component of the albuterol MDI, beta2 receptor-agonist drug, HFA, any related compounds or methacholine. 8. Need for daily oral corticosteroids within 3 months prior to screening. 9. Cardiac arrhythmia or 12-lead electrocardiogram (ECG) abnormalities, that in the opinion of the Investigator would compromise subject safety or interfere with the evaluations, or a QTc > 440 ms for males and > 460 ms for females using Fredericia formula. 10. Subjects receiving beta blocker via any route or who may require beta blockers during the study. 11. History of narrow angle glaucoma, convulsive disorders, hyperthyroidism, uncontrolled diabetes, paradoxical bronchospasm. 12. History of malignancies. 13. History of alcohol or drug abuse. 14. Eye, brain, thoracic, and abdominal surgeries within 3 months prior to screening. 15. Use of cromyolyn, leukotriene receptor antagonists (LTRA), nedocromil, zileuton, theophylline, or long-acting beta-agonists (LABA) within 1 month prior to screening. 16. History of receiving muscarinic beta2-agonists (MABAs), short-acting muscarinic antagonists (SAMAs), long-acting muscarinic antagonists (LAMAs), anti-IgE, anti-IL5/5R, anti-IL4R, high dose ICS, or systemic corticosteroid for treatment of asthma within 6 months prior to screening. 17. Known Human Immunodeficiency Virus (HIV)-positive status. 18. Participated in any interventional clinical trials within 1 month prior to screening. 19. Pregnancy or breast feeding.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Albuterol Sulfate inhalation aerosol 108 mcg per actuation
equal to albuterol 90 mcg/puff, MDI
Proair HFA (Albuterol Sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg per actuation
equal to albuterol 90 mcg/puff, MDI
Other:
Proair HFA or FDA authorized generic: Albuterol Sulfate HFA Inhalation Placebo
MDI
Albuterol Sulfate inhalation Placebo
MDI
Methacholine
Methacholine 100 mg/vial

Locations

Country Name City State
India Dr. Jivraj Mehta Smarak Health Foundation Ahmedabad
India KLEs Dr Prabhakar Kore Hospital & MRC Belagave
India Medical College and Hospital Kolkata
India NRS Medical College and Hospital Kolkata
India Aakash Healthcare Super Specialty Hospital New Delhi
India Kothrud Hospital Pune
India Pimpri Chinchwad Municipal Corporation Post Graduate Institute Yashwantrao Chavan Memorial Hospital Pune
India Ashirwad Hospital and Research Centre Ulhasnagar
Taiwan Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung City
Taiwan Tamshui Mackay Memorial Hospital New Taipei City
Taiwan Shin Kong Wu Ho-Su Memorial Hospital Taipei City
Taiwan Taipei Medical University Hospital Taipei City

Sponsors (1)

Lead Sponsor Collaborator
Intech Biopharm Ltd.

Countries where clinical trial is conducted

India,  Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Post-dose PC20 Concentration Post-dose PC20, which are the provocative concentrations, respectively, of the methacholine challenge agent required to reduce the forced expiratory volume in one second (FEV1) by 20% following administration of differing concentrations of albuterol (or placebo) by inhalation. 15 minutes post-dose
See also
  Status Clinical Trial Phase
Completed NCT00380354 - Study To Evaluate GSK256066 In Subjects With Mild Bronchial Asthma Phase 2
Completed NCT00453778 - A Study To Investigate The Effect Of Inhaled Fluticasone Propionate On The Bronchial Responsiveness To Leukotriene D4 In Asthmatics Patients Phase 4
Recruiting NCT04796844 - MANI Real-life Perspective Observatory
Completed NCT00466596 - Effect of House Dust Mite Allergen Challenge in Persons Using 1200 mg Gamma Tocopherol Supplements Phase 1
Not yet recruiting NCT06433921 - A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive Phase 1
Not yet recruiting NCT06411886 - Measurements of Inflammation Induced by Allergen Inhalation Challenge in Mild Allergic Asthma N/A
Completed NCT00287365 - Genetic Susceptibility to Ozone in Mild Asthmatic Volunteers N/A
Completed NCT02892344 - Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma Phase 3
Completed NCT00448851 - Study of Dust Mite Inhalation in Humans Phase 1
Completed NCT03838731 - Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge Phase 2
Completed NCT03421730 - A Study of the Pharmacokinetics, Safety and Tolerability of Single Doses of VR647 Inhalation Suspension Administered Using the VR647 Inhalation System in Children With Wheezing, Reactive Airway Disease or Mild Asthma Phase 1